Demographics and clinical characteristics of patients (n = 109)
| . | N (%) . |
|---|---|
| Follow-up duration median (IQR), mo | 96 (63-142) |
| Time from biopsy to initial treatment median (IQR), mo | 0.91 (0.35-1.68) |
| Sex | |
| Male | 61 (56.0) |
| Female | 48 (44.0) |
| Age, y | |
| ≤60 | 57 (53.3) |
| >60 | 50 (46.7) |
| Ann Arbor stage | |
| I-II | 7 (6.4) |
| III-IV | 102 (93.6) |
| B symptoms present | |
| No | 75 (68.8) |
| Yes | 34 (31.2) |
| Eastern Cooperative Oncology Group performance status | |
| 0-1 | 102 (93.6) |
| 2-4 | 7 (6.4) |
| Hemoglobin <12 g/dL | |
| No | 84 (77.1) |
| Yes | 25 (22.9) |
| Increased lactate dehydrogenase | |
| No | 87 (79.8) |
| Yes | 19 (17.4) |
| Not known | 3 (2.7) |
| Increased B2-microglobulin | |
| No | 65 (60.6) |
| Yes | 35 (32.1) |
| Not known | 8 (7.3) |
| Involved node >6 cm | |
| No | 82 (75.2) |
| Yes | 27 (24.8) |
| Bone marrow involvement | |
| No | 46 (42.2) |
| Yes | 56 (51.4) |
| Not known | 7 (6.4) |
| FLIPI score | |
| 0-1 | 18 (16.8) |
| 2 | 43 (40.2) |
| 3-5 | 42 (39.3) |
| Not known | 4 (3.7) |
| FLIPI-2 score | |
| 0 | 12 (11.0) |
| 1-2 | 49 (45.0) |
| 3-5 | 40 (37.7) |
| Not known | 8 (7.3) |
| PRIMA-PI score | |
| Low | 37 (33.9) |
| Intermediate | 29 (26.6) |
| High | 33 (30.3) |
| Not known | 10 (9.2) |
| m7-FLIPIscore | |
| Low | 81 (74.3) |
| High | 24 (22.0) |
| Not known | 4 (3.7) |
| Histological grade | |
| 1-2 | 57 (52.3) |
| 3a | 34 (31.2) |
| Not specified | 18 (16.5) |
| Induction regimen | |
| R-CHOP | 71 (65.1) |
| R-CVP | 8 (7.3) |
| R-B | 30 (27.5) |
| Maintenance regimen | |
| No | 14 (12.8) |
| Yes | 95 (87.2) |
| . | N (%) . |
|---|---|
| Follow-up duration median (IQR), mo | 96 (63-142) |
| Time from biopsy to initial treatment median (IQR), mo | 0.91 (0.35-1.68) |
| Sex | |
| Male | 61 (56.0) |
| Female | 48 (44.0) |
| Age, y | |
| ≤60 | 57 (53.3) |
| >60 | 50 (46.7) |
| Ann Arbor stage | |
| I-II | 7 (6.4) |
| III-IV | 102 (93.6) |
| B symptoms present | |
| No | 75 (68.8) |
| Yes | 34 (31.2) |
| Eastern Cooperative Oncology Group performance status | |
| 0-1 | 102 (93.6) |
| 2-4 | 7 (6.4) |
| Hemoglobin <12 g/dL | |
| No | 84 (77.1) |
| Yes | 25 (22.9) |
| Increased lactate dehydrogenase | |
| No | 87 (79.8) |
| Yes | 19 (17.4) |
| Not known | 3 (2.7) |
| Increased B2-microglobulin | |
| No | 65 (60.6) |
| Yes | 35 (32.1) |
| Not known | 8 (7.3) |
| Involved node >6 cm | |
| No | 82 (75.2) |
| Yes | 27 (24.8) |
| Bone marrow involvement | |
| No | 46 (42.2) |
| Yes | 56 (51.4) |
| Not known | 7 (6.4) |
| FLIPI score | |
| 0-1 | 18 (16.8) |
| 2 | 43 (40.2) |
| 3-5 | 42 (39.3) |
| Not known | 4 (3.7) |
| FLIPI-2 score | |
| 0 | 12 (11.0) |
| 1-2 | 49 (45.0) |
| 3-5 | 40 (37.7) |
| Not known | 8 (7.3) |
| PRIMA-PI score | |
| Low | 37 (33.9) |
| Intermediate | 29 (26.6) |
| High | 33 (30.3) |
| Not known | 10 (9.2) |
| m7-FLIPIscore | |
| Low | 81 (74.3) |
| High | 24 (22.0) |
| Not known | 4 (3.7) |
| Histological grade | |
| 1-2 | 57 (52.3) |
| 3a | 34 (31.2) |
| Not specified | 18 (16.5) |
| Induction regimen | |
| R-CHOP | 71 (65.1) |
| R-CVP | 8 (7.3) |
| R-B | 30 (27.5) |
| Maintenance regimen | |
| No | 14 (12.8) |
| Yes | 95 (87.2) |
Data are median (IQR) or n/N (%). Percentages might not add up to 100% because of rounding.
IQR, interquartile range.